- 1 Lixte Biotechnology Holdings Inc (NASDAQ: LIXT) stock added $2.10 in the July 17 trading session.
- 2 In Monday’s trading session, LIXT stock was trading near its last high of April 11.
Lixte Biotechnology Holdings Inc (NASDAQ: LIXT) stock added $2.10 in the July 17 trading session. It opened trading at $6.30, dipped to $5.32, hit a high of $9.50, and closed trading at $7.53 with an intraday trading volume of 4.454 million.
In the monthly time frame, LIXT stock surged over 55%, but in the 12-month time frame, the stock price reflected a decline of 5.84%. In the 52-week time frame, Lixte Biotechnology Holdings Inc’s stock lowest traded price was $4.32, and its highest trading price was $27.
In Monday’s trading session, LIXT stock was trading near its last high of April 11. In its previous trading session of July 17, the stock reflected a majority of buyers, which indicates that some giant investors might have invested a significant chunk in the market.
If buyers push the prices in the upward direction, it might hit its second last high of $27.00, which occurred in the February 7 trading session. If the buyer fails to sustain its immediate resistance, it might face support below $4.30.
Lixte Biotechnology Holdings Inc’s market capitalization is $12.544 million, and its average volume is 487.231k. TradingView shows that 862.699k Lixte shares are closely held, and the remaining 803.211k shares are free-floating.
What is Pushing LIXT Stock Up?
Lixte Biotechnology Holdings reported on Monday that research with the Netherlands Cancer Institute showed that the company’s primary clinical chemical, LB-100, can alter how colon cancer cells process their mRNAs by inhibiting an enzyme in the cells.
Early trading saw shares rise 25% to $6.77, putting the firm on track for its biggest percentage gain in a little over five months.The trade was halted four times due to volatility, and it was restarted at 10:55 a.m. ET.
In the short-term, the company’s assets are $5.41 million, and its liabilities are $394.79k. However, in the long-term, the company’s assets are $147.02k, and liabilities are nil. In quarter one 2023 operating income of Lixte Biotechnology was -$1.37 million.
Lixte Biotechnology Holdings, Inc is a clinical-stage pharmaceutical company that majorly works in the development of bio-maker technology to identify enzyme targets associated with serious common diseases and then designs novel compounds to attack the identified targets. The company was founded by John S. Kovach and Robert B. Royds on August 9, 2005.
The medical industry’s rapid response to the COVID-19 pandemic has been revolutionary. Scientific advances in just a few years have significantly benefited society as the virus has become less contagious and severe.
As the severe threat from the pandemic subsides, the healthcare industry is looking for new applications that take advantage of recent innovations.
mRNA vaccines effectively prevent the spread and reduce the severity of evolving variants of novel coronavirus disease (COVID-194). With more than 13 billion doses of the COVID-19 vaccine administered worldwide, the demand for subsequent COVID-19 boosters has declined.
The views and opinions stated by the author, or any people named in this article, are for informational ideas only and do not establish financial, investment, or other advice. Investing in or trading crypto assets comes with a risk of financial loss.
Andrew is a blockchain developer who developed his interest in cryptocurrencies while pursuing his post-graduation major in blockchain development. He is a keen observer of details and shares his passion for writing, along with coding. His backend knowledge about blockchain helps him give a unique perspective to his writing skills, and a reliable craft at explaining the concepts such as blockchain programming, languages and token minting. He also frequently shares technical details and performance indicators of ICOs and IDOs.